PI
AMLX icon

Putnam Investments’s Amylyx Pharmaceuticals AMLX Stock Holding History

Putnam Investments’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-46,460
Closed -$851K – 1154
2023
Q3 		$851K Sell
46,460
-402
-0.9% -$8.5K ﹤0.01% 857
2023
Q2 		$1.01M Sell
46,862
-1,459
-3% -$39.4K ﹤0.01% 844
2023
Q1 		$1.42M Buy
48,321
+25,289
+110% +$879K ﹤0.01% 807
2022
Q4 		$851K Sell
23,032
-13
-0.1% -$461 ﹤0.01% 857
2022
Q3 		$649K Buy
+23,045
New +$575K ﹤0.01% 903

Other funds holding AMLX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Putnam Investments's AMLX Position: Q4 2023 in Review

Putnam Investments sold out of Amylyx Pharmaceuticals (AMLX) in Q4 2023, closing a stake of 46,460 shares — an estimated $851K sold.

Putnam Investments first reported a position in AMLX in Q3 2022 and held it in 5 quarters. The position peaked at $1.42M in Q1 2023. 178 funds tracked by Wall St. Rank hold AMLX as of Q4 2023.

  • Putnam Investments reported no remaining Amylyx Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Putnam Investments sold 46,460 Amylyx Pharmaceuticals shares in Q4 2023, an estimated $851K.
  • Putnam Investments first reported a position in Amylyx Pharmaceuticals in Q3 2022 and held it in 5 quarters.
  • Putnam Investments's Amylyx Pharmaceuticals position peaked at $1.42M in Q1 2023.
  • 178 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q4 2023.

Based on Putnam Investments's 13F filing for Q4 2023, filed 14 Feb 2024.